Taysha Gene Therapies, Inc. TSHA
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.51% | 9.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.88% | 28.71% | |||
| Operating Income | -8.88% | -53.66% | |||
| Income Before Tax | -9.97% | -52.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.97% | -52.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.97% | -52.27% | |||
| EBIT | -8.88% | -53.66% | |||
| EBITDA | -8.95% | -54.25% | |||
| EPS Basic | -9.25% | -48.52% | |||
| Normalized Basic EPS | -9.46% | -84.17% | |||
| EPS Diluted | -9.25% | -48.52% | |||
| Normalized Diluted EPS | -9.46% | -84.17% | |||
| Average Basic Shares Outstanding | 0.66% | 2.61% | |||
| Average Diluted Shares Outstanding | 0.66% | 2.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||